Soleno Cost Of Revenue vs Revenue Per Share Analysis

SLNO Stock

USD 57.78 3.15 5.77%

Soleno Therapeutics financial indicator trend analysis is much more than just breaking down Soleno Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Soleno Therapeutics is a good investment. Please check the relationship between Soleno Therapeutics Cost Of Revenue and its Revenue Per Share accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Soleno Therapeutics Cost Of Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have weak relationship.

The correlation between Soleno Therapeutics' Cost Of Revenue and Revenue Per Share is 0.33. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of Soleno Therapeutics, assuming nothing else is changed. The correlation between historical values of Soleno Therapeutics' Cost Of Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Soleno Therapeutics are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Cost Of Revenue i.e., Soleno Therapeutics' Cost Of Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

0.33

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Soleno Therapeutics income statement and represents the costs associated with goods and services Soleno Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from Soleno Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Soleno Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.As of the 23rd of November 2024, Selling General Administrative is likely to drop to about 7.4 M. In addition to that, Discontinued Operations is likely to drop to about (1.8 M)

Soleno Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt
Total Assets		-0.41	0.04	0.09	0.98	0.34	0.66	0.51	-0.99	-0.81	0.57	0.99	0.37	0.0	-0.18	0.99	-0.49	0.78	0.94	-0.26	0.52	0.93	-0.18	0.71	0.99	-0.41
Short Long Term Debt Total	-0.41		0.85	0.74	-0.56	-0.65	-0.32	-0.99	0.43	0.63	-0.6	-0.34	-0.62	-0.17	-0.23	-0.34	0.62	-0.61	-0.39	0.83	-0.53	-0.61	0.87	-0.33	-0.35	1.0
Other Current Liab	0.04	0.85		0.93	-0.12	-0.62	0.0	-0.77	-0.02	0.17	-0.26	0.11	-0.53	-0.29	-0.37	0.11	0.41	-0.15	0.11	0.67	-0.19	-0.15	0.82	0.02	0.11	0.86
Total Current Liabilities	0.09	0.74	0.93		-0.07	-0.44	0.2	-0.64	-0.08	0.0	0.03	0.15	-0.38	-0.34	-0.45	0.15	0.18	0.04	0.19	0.66	0.06	-0.03	0.84	0.21	0.15	0.75
Total Stockholder Equity	0.98	-0.56	-0.12	-0.07		0.37	0.63	0.65	-0.98	-0.84	0.6	0.96	0.43	0.05	-0.08	0.96	-0.54	0.8	0.92	-0.43	0.55	0.95	-0.36	0.69	0.97	-0.56
Other Liab	0.34	-0.65	-0.62	-0.44	0.37		0.38	0.64	-0.32	-0.46	0.56	0.26	0.64	0.16	-0.27	0.27	-0.61	0.45	0.27	-0.13	0.4	0.43	-0.26	0.36	0.27	-0.66
Property Plant And Equipment Net	0.66	-0.32	0.0	0.2	0.63	0.38		0.41	-0.65	-0.74	0.69	0.65	0.3	-0.29	-0.22	0.64	-0.47	0.74	0.71	-0.13	0.55	0.72	-0.03	0.99	0.64	-0.32
Current Deferred Revenue	0.51	-0.99	-0.77	-0.64	0.65	0.64	0.41		-0.53	-0.73	0.69	0.44	0.63	0.13	0.18	0.45	-0.67	0.72	0.5	-0.82	0.63	0.71	-0.83	0.42	0.45	-0.99
Net Debt	-0.99	0.43	-0.02	-0.08	-0.98	-0.32	-0.65	-0.53		0.8	-0.57	-0.99	-0.31	0.03	0.16	-0.99	0.45	-0.77	-0.94	0.29	-0.51	-0.92	0.2	-0.71	-0.99	0.43
Retained Earnings	-0.81	0.63	0.17	0.0	-0.84	-0.46	-0.74	-0.73	0.8		-0.81	-0.77	-0.56	0.03	0.15	-0.77	0.76	-0.98	-0.9	0.47	-0.78	-0.96	0.35	-0.77	-0.77	0.63
Accounts Payable	0.57	-0.6	-0.26	0.03	0.6	0.56	0.69	0.69	-0.57	-0.81		0.52	0.54	-0.09	-0.2	0.52	-0.74	0.87	0.61	-0.37	0.92	0.73	-0.25	0.69	0.52	-0.6
Cash	0.99	-0.34	0.11	0.15	0.96	0.26	0.65	0.44	-0.99	-0.77	0.52		0.25	-0.05	-0.19	1.0	-0.38	0.73	0.94	-0.22	0.46	0.9	-0.13	0.71	1.0	-0.34
Non Current Assets Total	0.37	-0.62	-0.53	-0.38	0.43	0.64	0.3	0.63	-0.31	-0.56	0.54	0.25		0.4	-0.03	0.25	-0.92	0.56	0.28	-0.36	0.58	0.52	-0.4	0.29	0.25	-0.63
Non Currrent Assets Other	0.0	-0.17	-0.29	-0.34	0.05	0.16	-0.29	0.13	0.03	0.03	-0.09	-0.05	0.4		-0.07	-0.05	-0.28	-0.04	-0.11	-0.12	-0.07	0.0	-0.21	-0.27	-0.05	-0.18
Other Assets	-0.18	-0.23	-0.37	-0.45	-0.08	-0.27	-0.22	0.18	0.16	0.15	-0.2	-0.19	-0.03	-0.07		-0.19	0.06	-0.18	-0.23	-0.5	-0.11	-0.13	-0.52	-0.22	-0.19	-0.24
Cash And Short Term Investments	0.99	-0.34	0.11	0.15	0.96	0.27	0.64	0.45	-0.99	-0.77	0.52	1.0	0.25	-0.05	-0.19		-0.39	0.73	0.94	-0.22	0.46	0.9	-0.13	0.7	1.0	-0.34
Net Receivables	-0.49	0.62	0.41	0.18	-0.54	-0.61	-0.47	-0.67	0.45	0.76	-0.74	-0.38	-0.92	-0.28	0.06	-0.39		-0.75	-0.49	0.38	-0.76	-0.67	0.34	-0.46	-0.39	0.63
Common Stock Total Equity	0.78	-0.61	-0.15	0.04	0.8	0.45	0.74	0.72	-0.77	-0.98	0.87	0.73	0.56	-0.04	-0.18	0.73	-0.75		0.86	-0.45	0.83	0.94	-0.33	0.76	0.73	-0.61
Common Stock Shares Outstanding	0.94	-0.39	0.11	0.19	0.92	0.27	0.71	0.5	-0.94	-0.9	0.61	0.94	0.28	-0.11	-0.23	0.94	-0.49	0.86		-0.28	0.56	0.95	-0.15	0.77	0.94	-0.39
Non Current Liabilities Total	-0.26	0.83	0.67	0.66	-0.43	-0.13	-0.13	-0.82	0.29	0.47	-0.37	-0.22	-0.36	-0.12	-0.5	-0.22	0.38	-0.45	-0.28		-0.4	-0.47	0.96	-0.15	-0.23	0.82
Other Current Assets	0.52	-0.53	-0.19	0.06	0.55	0.4	0.55	0.63	-0.51	-0.78	0.92	0.46	0.58	-0.07	-0.11	0.46	-0.76	0.83	0.56	-0.4		0.69	-0.27	0.57	0.46	-0.53
Other Stockholder Equity	0.93	-0.61	-0.15	-0.03	0.95	0.43	0.72	0.71	-0.92	-0.96	0.73	0.9	0.52	0.0	-0.13	0.9	-0.67	0.94	0.95	-0.47	0.69		-0.37	0.77	0.9	-0.61
Total Liab	-0.18	0.87	0.82	0.84	-0.36	-0.26	-0.03	-0.83	0.2	0.35	-0.25	-0.13	-0.4	-0.21	-0.52	-0.13	0.34	-0.33	-0.15	0.96	-0.27	-0.37		-0.05	-0.13	0.87
Property Plant And Equipment Gross	0.71	-0.33	0.02	0.21	0.69	0.36	0.99	0.42	-0.71	-0.77	0.69	0.71	0.29	-0.27	-0.22	0.7	-0.46	0.76	0.77	-0.15	0.57	0.77	-0.05		0.71	-0.33
Total Current Assets	0.99	-0.35	0.11	0.15	0.97	0.27	0.64	0.45	-0.99	-0.77	0.52	1.0	0.25	-0.05	-0.19	1.0	-0.39	0.73	0.94	-0.23	0.46	0.9	-0.13	0.71		-0.34
Short Term Debt	-0.41	1.0	0.86	0.75	-0.56	-0.66	-0.32	-0.99	0.43	0.63	-0.6	-0.34	-0.63	-0.18	-0.24	-0.34	0.63	-0.61	-0.39	0.82	-0.53	-0.61	0.87	-0.33	-0.34

Click cells to compare fundamentals

Soleno Therapeutics Account Relationship Matchups

Soleno Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	38.2M	65.0M	35.6M	26.5M	180.7M	189.7M
Other Current Liab	382K	5.0M	4.2M	5.2M	7.8M	8.2M
Total Current Liabilities	5.0M	8.6M	8.0M	7.3M	11.5M	7.0M
Total Stockholder Equity	14.9M	45.5M	17.8M	10.3M	157.5M	165.4M
Other Liab	18.1M	10.8M	9.6M	8.8M	10.2M	9.1M
Property Plant And Equipment Net	444K	158K	454K	157K	419K	440.0K
Net Debt	(20.4M)	(49.1M)	(20.8M)	(14.4M)	(169.3M)	(160.8M)
Retained Earnings	(157.8M)	(182.4M)	(213.4M)	(237.4M)	(276.4M)	(262.6M)
Accounts Payable	2.0M	3.5M	3.3M	1.8M	3.1M	1.6M
Cash	20.7M	49.2M	21.3M	14.6M	169.7M	178.2M
Non Current Assets Total	17.0M	14.7M	13.1M	10.9M	9.3M	9.9M
Non Currrent Assets Other	59K	139K	40K	165K	148.5K	141.1K
Cash And Short Term Investments	20.7M	49.2M	21.3M	14.6M	169.7M	178.2M
Common Stock Total Equity	19.2K	32K	45K	80K	92K	96.6K
Common Stock Shares Outstanding	2.3M	4.2M	5.3M	8.4M	16.5M	17.3M
Liabilities And Stockholders Equity	38.2M	65.0M	35.6M	26.5M	180.7M	189.7M
Non Current Liabilities Total	18.3M	10.8M	9.8M	8.8M	11.7M	10.1M
Other Current Assets	411K	2.0M	2.2M	1.0M	1.7M	895.9K
Other Stockholder Equity	172.7M	227.9M	231.1M	247.8M	433.9M	455.6M
Total Liab	23.2M	19.4M	17.8M	16.1M	23.2M	15.1M
Property Plant And Equipment Gross	444K	158K	522K	157K	508K	533.4K
Total Current Assets	21.1M	50.2M	22.4M	15.6M	171.4M	179.9M
Common Stock	19.2K	32K	45K	80K	8K	30.7K
Property Plant Equipment	22K	19K	454K	157K	180.6K	110.1K
Net Tangible Assets	(1.6M)	31.0M	5.2M	(345K)	(396.8K)	(376.9K)
Retained Earnings Total Equity	(114.0M)	(127.0M)	(157.8M)	(182.4M)	(164.2M)	(172.4M)
Capital Surpluse	140.5M	157.4M	172.7M	227.9M	262.1M	149.3M
Deferred Long Term Liab	5.4M	5.2M	12.2M	539K	485.1K	460.8K
Intangible Assets	16.5M	14.6M	12.6M	10.7M	8.7M	11.4M
Non Current Liabilities Other	6.1M	10.3M	9.5M	8.8M	11.5M	7.0M
Net Invested Capital	14.9M	45.5M	17.8M	10.3M	157.5M	165.4M
Net Working Capital	16.2M	41.6M	14.4M	8.3M	159.9M	167.8M

Pair Trading with Soleno Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Soleno Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Soleno Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Soleno Stock

0.82	MTEM	Molecular Templates	Pair Corr
0.72	AGL	agilon health	Pair Corr
0.7	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.68	NKTX	Nkarta Inc	Pair Corr
0.66	VALN	Valneva SE ADR	Pair Corr

The ability to find closely correlated positions to Soleno Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Soleno Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Soleno Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Soleno Therapeutics to buy it.

The correlation of Soleno Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Soleno Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Soleno Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Soleno Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Soleno Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Soleno Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Soleno Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Soleno Therapeutics Stock:

How To Invest In Soleno

Details

Is Soleno Stock a good investment?

Details

What is Soleno Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Soleno Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

To learn how to invest in Soleno Stock, please use our How to Invest in Soleno Therapeutics guide.

You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Soleno Therapeutics. If investors know Soleno will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Soleno Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.79)

Return On Assets

(0.48)

Return On Equity

(0.91)

The market value of Soleno Therapeutics is measured differently than its book value, which is the value of Soleno that is recorded on the company's balance sheet. Investors also form their own opinion of Soleno Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Soleno Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Soleno Therapeutics' market value can be influenced by many factors that don't directly affect Soleno Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Soleno Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Soleno Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Soleno Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Soleno Cost Of Revenue vs Revenue Per Share Analysis

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Revenue Per Share

Soleno Therapeutics fundamental ratios Correlations

Soleno Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Soleno Therapeutics fundamental ratios Accounts

Pair Trading with Soleno Therapeutics

Moving against Soleno Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Short Term Debt	+ 1.0	Short Long Term Debt Total
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Short Term Debt	- 0.99	Current Deferred Revenue
Current Deferred Revenue	- 0.99	Short Long Term Debt Total
Net Debt	- 0.99	Total Assets